Duchenne muscular dystrophy drug shows favourable PK profile
Satellos Bioscience has shared positive initial Phase I data for its small molecule drug candidate SAT-3247 at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas. SAT-3247 is designed to address progressive muscle loss in Duchenne muscular dystrophy (DMD) patients by aiming to… Read More